Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01345630 · ClinicalTrials.gov registry record · Phase 3
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1
A Phase 3 study, sponsored by ViiV Healthcare.
- Terminated
- Registry status
- Phase 3
- Development phase
- 813
- Enrollment target
NCT01345630 is a Phase 3 study that was terminated before completion, run by ViiV Healthcare. The registered enrollment target is 813 participants.
The verdict
NCT01345630, a Phase 3 study, was terminated before completion, sponsored by ViiV Healthcare.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 813 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether maraviroc administered once daily is non-inferior to emtricitabine/tenofovir also administered once daily each in combination with darunavir/ritonavir in the treatment of antiretroviral-naive patients as evaluated at Week 48 of treatment.
Interventions
- DRUG Maraviroc
- DRUG Emtricitabine/tenofovir
- DRUG darunavir/ritonavir 800/100 mg
- DRUG placebo for emtricitabine/tenofovir
- DRUG placebo for maraviroc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 813 participants |
| Start Date | 2011-09 |
| Est. Completion | 2014-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01345630
The ClinicalTrials.gov registry entry for NCT01345630 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 813 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Maraviroc is the first listed.
NCT01345630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01345630 about?
NCT01345630 is a clinical study titled "Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1". The purpose of this study is to assess whether maraviroc administered once daily is non-inferior to emtricitabine/tenofovir also administered once daily each in combination with darunavir/ritonavir in the treatment of antiretroviral-naive patients as evaluated at Week 48 of treatment.
What is the current status of trial NCT01345630?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 813 participants. The study started on 2011-09. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01345630?
The interventions under investigation include: Maraviroc (DRUG), Emtricitabine/tenofovir (DRUG), darunavir/ritonavir 800/100 mg (DRUG), placebo for emtricitabine/tenofovir (DRUG), placebo for maraviroc (DRUG).
Who is sponsoring clinical trial NCT01345630?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.